Nephrotic syndrome with dense deposit disease
Methodology & AI Transparency ⓘ
Nephrotic syndrome with dense deposit disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N04.6), workup for Nephrotic syndrome with dense deposit disease integrates NSAID/nephrotoxin avoidance [Nephrotic syndrome with dense deposit disease N04.6] with evidence-graded therapy tailored to eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code N04.6 categorizes Nephrotic syndrome with dense deposit disease under Chronic Kidney Disease & Electrolytes.
- 3 Typical cash cost range: Workup highlights for Nephrotic syndrome with dense deposit disease (N04.6): NSAID/nephrotoxin avoidance [Nephrotic syndrome with dense deposit disease N04.6].
- 4 Top reported side effects / signs: Longitudinal Nephrotic syndrome with dense deposit disease monitoring tracks eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)) toward >= 90 mL/min/1.73m2 (N04.6).
Ask our AI Specialists anything about Nephrotic syndrome with dense deposit disease
What Is Nephrotic syndrome with dense deposit disease?
Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N04.6), workup for Nephrotic syndrome with dense deposit disease integrates NSAID/nephrotoxin avoidance [Nephrotic syndrome with dense deposit disease N04.6] with evidence-graded therapy tailored to eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Nephrotic syndrome with dense deposit disease (N04.6) center on tubulointerstitial fibrosis [Nephrotic syndrome with dense deposit disease N04.6]. targeted kidney & renal interventions aim to normalize eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)).
Common Symptoms & Clinical Signs
- • Presentation of Nephrotic syndrome with dense deposit disease (N04.6): asymptomatic decline in in Nephrotic syndrome with dense deposit disease (N04.6: eGFR or persistent)
- • Secondary Nephrotic syndrome with dense deposit disease clinical sign: fluid retention in in Nephrotic syndrome with dense deposit disease (N04.6: ankles, hands, or)
- • Symptom flares in Nephrotic syndrome with dense deposit disease correlating with eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)) deviation outside >= 90 mL/min/1.73m2 (N04.6)
- • Functional kidney & renal impact requiring NSAID/nephrotoxin avoidance [Nephrotic syndrome with dense deposit disease N04.6] evaluation (N04.6)
Nephrotic syndrome with dense deposit disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N04.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Nephrotic syndrome with dense deposit disease (N04.6: Cystatin C)) | >= 90 mL/min/1.73m2 (N04.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome with dense deposit disease (N04.6: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N04.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Nephrotic syndrome with dense deposit disease (N04.6: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nephrotic syndrome with dense deposit disease
Treatment selection for Nephrotic syndrome with dense deposit disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nephrotic syndrome with dense deposit disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Circulating kidney injury molecule-1 (KIM-1) and association with outcome to These analyses suggest that elevated post-nephrectomy plasma KIM-1 level and kinetics are prognostic, supporting the hypothesis that KIM-1 is a biomarker for minimal residual disease in RCC. Annals of oncology : official journal of the European Society for Medical Oncology • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40885527 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Upacicalcet in Hemodialysis Patients with Secondary Upacicalcet, a novel injectable calcimimetic, is effective and safe for secondary hyperparathyroidism patients receiving HD. Clinical journal of the American Society of Nephrology : CJASN • 2023-10-01 • Phase III Randomized Trial | N = 103 | 88/100 | PMID 37696667 ↗ |
| Can This Approach Help? Inside the Latest Research on Bevacizumab-induced high blood pressure and proteinuria: a genome-wide study of The results from the largest study of bevacizumab toxicity provide new markers of drug safety for further evaluations. British journal of cancer • 2022-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34616010 ↗ |
| Can This Approach Help? Inside the Latest Research on Randomized study of the tolerability and efficacy of combination therapy for Addition of diuretics, CCB, or ACEI to ARB was equally effective for the control of high blood pressure in CKD, while, in terms of urinary excretion of protein, diuretics may be better than CCB. Clinical and experimental nephrology • 2015-10-15 • Randomized Controlled Trial | N = 37 | 82/100 | PMID 25680887 ↗ |
Nephrotic syndrome with dense deposit disease Patient Community & “People Like Me” Threads
Filter Nephrotic syndrome with dense deposit disease community threads and patient logs by age, biological sex, dosage, and treatment duration.